

INTRODUCTION

The CD38-targeting MoAb daratumumab when added to PI, IMiD or PI+ IMiD combinations increases the depth and duration of responses in NDMM, including patients treated with AHCT.

EUROPEAN

HEMATOLOGY

ASSOCIATION

Carfilzomib, a second generation, irreversible PI, is superior to bortezomib in RRMM and, when combined with Rd, leads to high rates of \geq VGPR in NDMM.

While responses are heterogeneous, treatment combinations have traditionally been developed with fixed number of cycles, not accounting for kinetics or depth of response

Response-adapted therapy for achievement of MRD (-) status has not been formally tested.

Natural history of patients with confirmed MRD (-) responses managed without maintenance has not been described

OBJECTIVE

To test the safety and activity of Dara-KRd in patients with NDMM and the feasibility of measurable residual disease (MRD)-guided post autologous transplantation (AHCT) consolidation and treatment-free observation with MRD-surveillance (TREFOMS) upon achievement of confirmed MRD negative status.

METHODS

Key eligibility:NDMM with measurable disease; Untreated (up to 1 cycle of VCD allowed); No age limit; ECOG 0-2; CrCl \geq 40 ml/min; No significant cardiopulmonary disease, concomitant or recent malignancy


Primary Endpoint

• Rate of MRD(-) responses (<10⁻⁵) utilizing NGS (clonoSEQ[®])in patients treated with Dara-KRd induction, AHCT, and MRD-based response-adapted Dara-KRd consolidation.

Key Secondary/Exploratory endpoints

- Toxicity of Dara-KRd
- Frequency of imaging plus MRD (-) CR
- MRD (-) rates by NGS with threshold of 10⁻⁶
- Outcomes of observation without maintenance upon confirmed MRD (-)

Dara-KRd: Daratumumab 16 mg/m² days 1,8,15,22 (days 1,15 C 3-6; day 1 C >6); Carfilzomib (20) 56 mg/m² Days 1,8,15; Lenalidomide 25 mg Days 1-21; Dexamethasone 40mg PO Days 1,8,15,22



*24 and 72 weeks after completion of therapy

Daratumumab, Carfilzomib, Lenalidomide and Dexamethasone (Dara-KRD) Induction, Autologous Transplantation and MRD Response-Adapted Consolidation in Newly Diagnosed Multiple Myeloma

L COSTA¹, S CHHABRA², K GODBY¹, E MEDVEDOVA³, R CORNELL⁴, A HALL⁵, B DHAKAL², S GIRI¹, S BAL¹, R SILBERMANN³, L DEIDIAQUEZ¹, A D'SOUZA², P HARDWICK¹, J OMEL⁶, Y BIRU⁶, N CALLANDER⁵, P HARI² 1-University of Alabama at Birmingham; 2- Medical College of Wisconsin; 3- Oregon Health Sciences University; 5-University; 5-University of Wisconsin; 6- Independent Patient Advocate

RESULTS

101 patients recruited, 82 completed induction, 63 completed post AHCT assessment (data cut Feb 2020)

Patient characteristics

- 19% ISS 3,


anemia (11%).

There were two deaths without progression (metapneumovirus pneumonia and sudden death, both after AHCT and before consolidation) and 1 progression.

IMWG traditional response

- 91% ≥VGPR after induction

None of the 40 patients who have so far achieved confirmed MRD negative status and entered TREFOMS had progression or resurgence of MRD (follow up 0.7-15.3 months).



• Median age: 61 years (range 35-79) years,

• 29% have high-risk chromosomal abnormalities [del17p, t(4;14) or t(14;16)].

96% have MRD trackable by clonoSEQ[®].

Most common grade 3 and 4 AEs were neutropenia (25%), lymphopenia (23%), infection (12%) and

92% ≥CR post AHCT and MRD-guided consolidation

CONCLUSIONS Dara-KRd is a safe regimen with rapid responses and unprecedented rates of MRD negative responses in NDMM. • NGS MRD-based, response adapted therapy is feasible in ~96% of patients in multi center setting. Intense, quadruplet therapy and achievement of confirmed MRD (-) CR may enable safe transition to observation/MRD surveillance and reduce the physical and financial burden of continuous therapy. Accrual is continuing and will reach 123 patients to further inform outcomes by cytogenetic subsets ACKNOWLEDGEMENTS Performed by Academic Consortium to Overcome Multiple <u>Myeloma through Innovative Trials (COMMIT)</u> OREGON HEALTH &SCIENCE VANDERBIL UNIVERSITY .5 Investigator-initiated trial, support from Amgen and Janssen Adaptive Biotechnologies for partnership and assistance with IDE.

CONTACT INFORMATION

ljcosta@uabmc.edu